Predictive relevance of miR‑34a, miR‑224 and miR‑342 in patients with advanced squamous cell carcinoma of the lung undergoing palliative chemotherapy

Kulda,Vlastimil; Svaton,Martin; Mukensnabl,Petr; Hrda,Kristyna; Dvorak,Pavel; Houdek,Zbynek; Houfkova,Katerina; Vrzakova,Radana; Babuska,Vaclav; Pesek,Milos; Pesta,Martin

doi:10.3892/ol.2017.7337

Predictive relevance of miR‑34a, miR‑224 and miR‑342 in patients with advanced squamous cell carcinoma of the lung undergoing palliative chemotherapy

Authors:
- Vlastimil Kulda
- Martin Svaton
- Petr Mukensnabl
- Kristyna Hrda
- Pavel Dvorak
- Zbynek Houdek
- Katerina Houfkova
- Radana Vrzakova
- Vaclav Babuska
- Milos Pesek
- Martin Pesta
View Affiliations

Affiliations: Department of Medical Chemistry and Biochemistry, Faculty of Medicine in Pilsen, Charles University, 30166 Pilsen, Czech Republic, Department of Pneumology and Phthisiology, Faculty of Medicine in Pilsen, Charles University, 30166 Pilsen, Czech Republic, Department of Pathology, Faculty of Medicine in Pilsen, Charles University, 30166 Pilsen, Czech Republic, Department of Biology, Faculty of Medicine in Pilsen, Charles University, 30166 Pilsen, Czech Republic
Published online on: November 2, 2017 https://doi.org/10.3892/ol.2017.7337
Pages: 592-599

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Attributing to their pathophysiological role and stability in biological samples, microRNAs (miRNAs) have the potential to become valuable predictive markers for non‑small cell lung cancer (NSCLC). Samples of biopsy tissue constitute suitable material for miRNA profiling with the aim of predicting the effect of palliative chemotherapy. The present study group included 81 patients (74 males, 7 females, all smokers or former smokers) with the squamous cell carcinoma (SCC) histological subtype of NSCLC at a late stage (3B or 4). All patients received palliative chemotherapy based on platinum derivatives in combination with paclitaxel or gemcitabine. The expression of 17 selected miRNAs was measured by reverse transcription‑quantitative polymerase chain reaction in tumor tissue macrodissected from formalin‑fixed paraffin‑embedded (FFPE) tissue samples. To predict the effect of palliative chemotherapy, the association between gene expression levels and overall survival (OS) time was analyzed. From the 17 miRNAs of interest, low expression levels of miR‑342 and high expression levels of miR‑34a and miR‑224 were associated with a reduced OS time in subgroups of patients based on smoking status and treatment modality. Using cluster analysis, associations between combinations of miR‑34a, ‑224 and ‑342 expression levels with patient survival were identified. The present study revealed that patients with the simultaneous high expression of miR‑224 and ‑342 had a similar prognostic outcome to those with the low expression of miR‑224 and ‑342, which was significantly reduced, compared with patients exhibiting high expression of either miR‑224 or miR‑342 with low expression of the other. We hypothesize that the effect of a particular miRNA is dependent on the expression level of other members of the miRNA network. This finding appears to complicate survival analyses based on individual miRNAs as markers. In conclusion, the present study provides evidence that specific miRNAs were associated with OS time, which may be candidate predictors for the effectiveness of palliative treatment in SCC lung cancer patients. This objective can be better achieved by combining more markers together than by using individual miRNAs.

View Figures

View References

1	Torre LA, Siegel RL and Jemal A: Lung Cancer Statistics. Adv Exp Med Biol. 893:1–19. 2016. View Article : Google Scholar : PubMed/NCBI
2	Institute of Health Information and Statistics of the Czech Republic, . Czech Health Statistics Year Book 2013UZIS CR. Prague: 2014
3	Travis WD: Pathology of lung cancer. Clin Chest Med. 32:669–692. 2011. View Article : Google Scholar : PubMed/NCBI
4	Socinski MA, Obasaju C, Gandara D, Hirsch FR, Bonomi P, Bunn P, Kim ES, Langer CJ, Natale RB, Novello S, et al: Clinicopathologic features of advanced squamous NSCLC. J Thorac Oncol. 11:1411–1422. 2016. View Article : Google Scholar : PubMed/NCBI
5	Olaussen KA and Postel-Vinay S: Predictors of chemotherapy efficacy in non-small-cell lung cancer: A challenging landscape. Ann Oncol. 27:2004–2016. 2016. View Article : Google Scholar : PubMed/NCBI
6	Inamura K and Ishikawa Y: MicroRNA in lung cancer: Novel biomarkers and potential tools for treatment. J Clin Med. 5:pii: E362016. View Article : Google Scholar
7	Griffiths-Jones S, Saini HK, van Dongen S and Enright AJ: miRBase: Tools for microRNA genomics. Nucleic Acids Res. 36(Database Issue): D154–D158. 2008.PubMed/NCBI
8	Friedman RC, Farh KK, Burge CB and Bartel DP: Most mammalian mRNAs are conserved targets of microRNAs. Genome Res. 19:92–105. 2009. View Article : Google Scholar : PubMed/NCBI
9	Sobin LH, Gospodarowicz MK and Wittekind Ch: TNM Classification of Malignant Tumours. 7th. Wiley-Blackwell; Chichester: 2010
10	Kalfert D, Pesta M, Kulda V, Topolcan O, Ryska A, Celakovsky P, Laco J and Ludvikova M: MicroRNA profile in site-specific head and neck squamous cell cancer. Anticancer Res. 35:2455–2463. 2015.PubMed/NCBI
11	Smid D, Kulda V, Srbecka K, Kubackova D, Dolezal J, Daum O, Kucera R, Topolcan O, Treska V, Skalicky T and Pesta M: Tissue microRNAs as predictive markers for gastric cancer patients undergoing palliative chemotherapy. Int J Oncol. 48:2693–2703. 2016.PubMed/NCBI
12	Mazumdar M and Glassman JR: Categorizing a prognostic variable: Review of methods, code for easy implementation and applications to decision-making about cancer treatments. Stat Med. 19:113–132. 2000. View Article : Google Scholar : PubMed/NCBI
13	Faraggi D and Simon R: A simulation study of cross-validation for selecting an optimal cutpoint in univariate survival analysis. Stat Med. 15:2203–2213. 1996. View Article : Google Scholar : PubMed/NCBI
14	Vlachos IS, Paraskevopoulou MD, Karagkouni D, Georgakilas G, Vergoulis T, Kanellos I, Anastasopoulos IL, Maniou S, Karathanou K, Kalfakakou D, et al: DIANA-TarBase v7.0: Indexing more than half a million experimentally supported miRNA:mRNA interactions. Nucleic Acids Res. 43(Database Issue): D153–D159. 2015. View Article : Google Scholar : PubMed/NCBI
15	Vlachos IS, Zagganas K, Paraskevopoulou MD, Georgakilas G, Karagkouni D, Vergoulis T, Dalamagas T and Hatzigeorgiou AG: DIANA-miRPath v3.0: Deciphering microRNA function with experimental support. Nucleic Acids Res. 43:W460–W466. 2015. View Article : Google Scholar : PubMed/NCBI
16	Khan J, Lieberman JA and Lockwood CM: Variability in, variability out: Best practice recommendations to standardize pre-analytical variables in the detection of circulating and tissue microRNAs. Clin Chem Lab Med. 55:608–621. 2017. View Article : Google Scholar : PubMed/NCBI
17	Cui R, Kim T, Fassan M, Meng W, Sun HL, Jeon YJ, Vicentini C, Tili E, Peng Y and Scarpa A: MicroRNA-224 is implicated in lung cancer pathogenesis through targeting caspase-3 and caspase-7. Oncotarget. 6:21802–21815. 2015. View Article : Google Scholar : PubMed/NCBI
18	Wang H, Zhu LJ, Yang YC, Wang ZX and Wang R: MiR-224 promotes the chemoresistance of human lung adenocarcinoma cells to cisplatin via regulating G1/S transition and apoptosis by targeting p21(WAF1/CIP1). Br J Cancer. 111:339–354. 2014. View Article : Google Scholar
19	Zhu D, Chen H, Yang X, Chen W, Wang L, Xu J and Yu L: Decreased microRNA-224 and its clinical significance in non-small cell lung cancer patients. Diagn Pathol. 9:1982014. View Article : Google Scholar
20	Wang L, Liu W, Zhang YP and Huang XR: The miR-224 promotes non-small cell lung cancer cell proliferation by directly targeting RASSF8. Eur Rev Med Pharmacol Sci. 21:3223–3231. 2017.
21	Xie X, Liu H, Wang M, Ding F, Xiao H, Hu F, Hu R and Mei J: miR-342-3p targets RAP2B to suppress proliferation and invasion of non-small cell lung cancer cells. Tumour Biol. 36:5031–5038. 2015. View Article : Google Scholar
22	Tai MC, Kajino T, Nakatochi M, Arima C, Shimada Y, Suzuki M, Miyoshi H, Yatabe Y, Yanagisawa K and Takahashi T: miR-342-3p regulates MYC transcriptional activity via direct repression of E2F1 in human lung cancer. Carcinogenesis. 36:1464–1473. 2015.
23	Takahashi K, Yokota SI, Tatsumi N, Fukami T, Yokoi T and Nakajima M: Cigarette smoking substantially alters plasma microRNA profiles in healthy subjects. Toxicol Appl Pharmacol. 272:154–160. 2013. View Article : Google Scholar
24	Rokavec M, Li H, Jiang L and Hermeking H: The p53/miR-34 axis in development and disease. J Mol Cell Biol. 6:214–230. 2014. View Article : Google Scholar
25	Okada N, Lin CP, Ribeiro MC, Biton A, Lai G, He X, Bu P, Vogel H, Jablons DM, Keller AC, et al: A positive feedback between p53 and miR-34 miRNAs mediates tumor suppression. Genes Dev. 28:438–450. 2014. View Article : Google Scholar
26	Navarro F and Lieberman J: miR-34 and p53: New insights into a complex functional relationship. PLoS One. 10:e01327672015. View Article : Google Scholar
27	Ma ZL, Hou PP, Li YL, Wang DT, Yuan TW, Wei JL, Zhao BT, Lou JT, Zhao XT, Jin Y and Jin YX: MicroRNA-34a inhibits the proliferation and promotes the apoptosis of non-small cell lung cancer H1299 cell line by targeting TGFβR2. Tumour Biol. 36:2481–2490. 2015. View Article : Google Scholar
28	Gallardo E, Navarro A, Viñolas N, Marrades RM, Diaz T, Gel B, Quera A, Bandres E, Garcia-Foncillas J, Ramirez J and Monzo M: miR-34a as a prognostic marker of relapse in surgically resected non-small-cell lung cancer. Carcinogenesis. 30:1903–1909. 2009. View Article : Google Scholar
29	Franchina T, Amodeo V, Bronte G, Savio G, Ricciardi GR, Picciotto M, Russo A, Giordano A and Adamo V: Circulating miR-22, miR-24 and miR-34a as novel predictive biomarkers to pemetrexed-based chemotherapy in advanced non-small cell lung cancer. J Cell Physiol. 229:97–99. 2014.
30	Goto Y, Nishikawa R, Kojima S, Chiyomaru T, Enokida H, Inoguchi S, Kinoshita T, Fuse M, Sakamoto S, Nakagawa M, et al: Tumour-suppressive microRNA-224 inhibits cancer cell migration and invasion via targeting oncogenic TPD52 in prostate cancer. FEBS Lett. 588:1973–1982. 2014. View Article : Google Scholar
31	Zhang Y, Li CF, Ma LJ, Ding M and Zhang B: MicroRNA-224 aggrevates tumor growth and progression by targeting mTOR in gastric cancer. Int J Oncol. 49:1068–1080. 2016.
32	Adamopoulos PG, Kontos CK, Rapti SM, Papadopoulos IN and Scorilas A: miR-224 overexpression is a strong and independent prognosticator of short-term relapse and poor overall survival in colorectal adenocarcinoma. Int J Oncol. 46:849–859. 2015. View Article : Google Scholar
33	Cui R, Meng W, Sun HL, Kim T, Ye Z, Fassan M, Jeon YJ, Li B, Vicentini C, Peng Y, et al: MicroRNA-224 promotes tumor progression in nonsmall cell lung cancer. Proc Natl Acad Sci USA. 112:pp. E4288–E4297. 2015; View Article : Google Scholar
34	Tay Y, Rinn J and Pandolfi PP: The multilayered complexity of ceRNA crosstalk and competition. Nature. 505:344–352. 2014. View Article : Google Scholar
35	Zhao Z, Zhang L, Yao Q and Tao Z: miR-15b regulates cisplatin resistance and metastasis by targeting PEBP4 in human lung adenocarcinoma cells. Cancer Gene Ther. 22:108–114. 2015. View Article : Google Scholar
36	Lin L, Tu HB, Wu L, Liu M and Jiang GN: MicroRNA-21 regulates non-small cell lung cancer cell invasion and chemo-sensitivity through SMAD7. Cell Physiol Biochem. 38:2152–2162. 2016. View Article : Google Scholar
37	Wang S, Su X, Bai H, Zhao J, Duan J, An T, Zhuo M, Wang Z, Wu M, Li Z, et al: Identification of plasma microRNA profiles for primary resistance to EGFR-TKIs in advanced non-small cell lung cancer (NSCLC) patients with EGFR activating mutation. J Hematol Oncol. 8:1272015. View Article : Google Scholar
38	Song C, Lu P, Sun G, Yang L and Wang Z and Wang Z: miR-34a sensitizes lung cancer cells to cisplatin via p53/miR-34a/MYCN axis. Biochem Biophys Res Commun. 482:22–27. 2017. View Article : Google Scholar
39	Chen C, Zhao Z, Liu Y and Mu D: microRNA-99a is downregulated and promotes proliferation, migration and invasion in non-small cell lung cancer A549 and H1299 cells. Oncol Lett. 9:1128–1134. 2015.
40	Ma Y, Li X, Cheng S, Wei W and Li Y: MicroRNA-106a confers cisplatin resistance in non-small cell lung cancer A549 cells by targeting adenosine triphosphatase-binding cassette A1. Mol Med Rep. 11:625–632. 2015. View Article : Google Scholar
41	Zhang Z, Zhang L, Yin ZY, Fan XL, Hu B, Wang LQ and Zhang D: miR-107 regulates cisplatin chemosensitivity of A549 non small cell lung cancer cell line by targeting cyclin dependent kinase 8. Int J Clin Exp Pathol. 7:7236–7241. 2014.
42	Zhang N, Su Y and Xu L: Targeting PKCε by miR-143 regulates cell apoptosis in lung cancer. FEBS Lett. 587:3661–3667. 2013. View Article : Google Scholar
43	Gu XY, Wang J, Luo YZ, Du Q, Li RR, Shi H and Yu TP: Down-regulation of miR-150 induces cell proliferation inhibition and apoptosis in non-small-cell lung cancer by targeting BAK1 in vitro. Tumour Biol. 35:5287–5293. 2014. View Article : Google Scholar
44	Cao J, He Y, Liu HQ, Wang SB, Zhao BC and Cheng YS: MicroRNA 192 regulates chemo-resistance of lung adenocarcinoma for gemcitabine and cisplatin combined therapy by targeting Bcl-2. Int J Clin Exp Med. 8:12397–12403. 2015.
45	Yu T, Li J, Yan M, Liu L, Lin H, Zhao F, Sun L, Zhang Y, Cui Y, Zhang F, et al: MicroRNA-193a-3p and −5p suppress the metastasis of human non-small-cell lung cancer by downregulating the ERBB4/PIK3R3/mTOR/S6K2 signaling pathway. Oncogene. 34:413–423. 2015. View Article : Google Scholar
46	Ye L, Wang H and Liu B: miR-211 promotes non-small cell lung cancer proliferation by targeting SRCIN1. Tumour Biol. 37:1151–1157. 2016. View Article : Google Scholar
47	Xie J, Yu F, Li D, Zhu X, Zhang X and Lv Z: MicroRNA-218 regulates cisplatin (DPP) chemosensitivity in non-small cell lung cancer by targeting RUNX2. Tumour Biol. 37:1197–1204. 2016. View Article : Google Scholar
48	Garofalo M, Di Leva G, Romano G, Nuovo G, Suh SS, Ngankeu A, Taccioli C, Pichiorri F, Alder H, Secchiero P, et al: miR-221&222 regulate TRAIL resistance and enhance tumorigenicity through PTEN and TIMP3 downregulation. Cancer Cell. 16:498–509. 2009. View Article : Google Scholar
49	Berghmans T, Ameye L, Willems L, Paesmans M, Mascaux C, Lafitte JJ, Meert AP, Scherpereel A, Cortot AB, Cstoth I, et al: Identification of microRNA-based signatures for response and survival for non-small cell lung cancer treated with cisplatin-vinorelbine A ELCWP prospective study. Lung Cancer. 82:340–345. 2013. View Article : Google Scholar
50	Fiedler SD, Carletti MZ and Christenson LK: Quantitative RT-PCR methods for mature microRNA expression analysis. Methods Mol Biol. 630:49–64. 2010. View Article : Google Scholar